Overview
Analysis Key terms
About Baxalta Incorporated 4.0% 23-JUN-2025
Sector
Health Technology
Industry
Biotechnology
Home page
FIGI
BBG00CTG55C6
Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL.
Advanced bond data for paid plans
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.